Precigen
PGEN
147 hedge funds and large institutions have $117M invested in Precigen in 2025 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 46 increasing their positions, 32 reducing their positions, and 13 closing their positions.
77% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 13
44% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 32
7% more funds holding
Funds holding: 138 → 147 (+9)
0.5% more ownership
Funds ownership: 27.31% → 27.8% (+0.5%)
6% less capital invested
Capital invested by funds: $124M → $117M (-$7.91M)
48% less call options, than puts
Call options by funds: $964K | Put options by funds: $1.85M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.43M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.39M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$852K |
| 4 |
BlackRock
New York
|
+$559K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$525K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$2.34M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.93M |
| 3 |
PCM
Patient Capital Management
Baltimore,
Maryland
|
-$1.57M |
| 4 |
Renaissance Technologies
New York
|
-$718K |
| 5 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
-$436K |
PGEN Hedge Fund Activity: Q2 2025 in Review
147 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Precigen (PGEN) for Q2 2025, worth a combined $117M — down 6.4% from $124M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new PGEN positions and 13 closed out — a net gain of 10 holders — while 46 added to existing stakes and 32 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $1.43M. The largest seller was Parkman Healthcare Partners, cutting an estimated $2.34M.
- 147 institutional investors held Precigen (PGEN) as of Q2 2025, up from 138 in Q1 2025.
- Funds reported $117M of Precigen stock for Q2 2025, down 6.4% quarter-over-quarter.
- 23 funds opened new Precigen positions in Q2 2025 and 13 closed out, a net change of +10 holders.
- The largest Precigen buyer in Q2 2025 was Morgan Stanley, an estimated $1.43M added.
- The largest Precigen seller in Q2 2025 was Parkman Healthcare Partners, an estimated $2.34M sold.
Based on aggregated 13F filings for Q2 2025.